In a real-world setting, less than a quarter of patients diagnosed with depression improved with medication, hospitalization, and therapy.
Nassir Ghaemi: “Most psychiatric medications are purely symptomatic, with no known or proven effect on the underlying disease. They are like 50 variations of aspirin, used for fever or headache, rather than drugs that treat the causes of fever or headache.”
Researchers found that 25% of elderly patients taking antidepressants had serotonin syndrome, which is potentially life-threatening.
Researchers highlight how systematic reviews are compromised by pharmaceutical industry ties by exposing a study of injectable antipsychotics.
“Efforts to improve learning in children with ADHD should focus on obtaining effective academic instruction rather than stimulant medication.”
Risk of depression increased when children were taking methylphenidate for ADHD, but once they stopped taking the drug, depression risk dropped to normal levels.
A new study reveals many benzodiazepine users are misinformed about the risks of withdrawal and experience devastating consequences.
Mark Horowitz and David Taylor provide advice on how to tell the difference between antidepressant withdrawal and depression relapse.
With the chemical imbalance theory falling out of fashion, researchers examine the claim that psychiatry never truly endorsed it.
A new study found that taking antidepressants did not improve quality of life.
According to patient reports, SSRI antidepressants most frequently lead to the subjective experience of emotional blunting.
Hospitalized COVID patients over 65 were three times as likely to receive a dementia diagnosis if they took psychiatric drugs.
New research examines service user attitudes on discontinuing and reducing antipsychotic drugs.
New research reveals that patients are often not given fully informed consent before being prescribed antipsychotics.
Withholding antipsychotics may be beneficial for memory, the researchers write.
A review of clinical practice guidelines for antidepressant discontinuation from across the English-speaking world reveals major pitfalls.
Supportive patient-practitioner relationships are crucial to the successful discontinuation of psychiatric medication.
Researchers argue that we need a paradigm shift away from the biomedical model of mental illness to one informed by political action and common sense.
Antidepressant trials with negative results are still more likely than not to either be misleadingly spun as positive or unpublished.
A study in JAMA Neurology finds that antidepressants do not reduce depression symptoms more than placebo in patients recovering from a stroke.
A review of research on antidepressant efficacy finds that an unfavorable risk-to-benefit ratio.
Researchers argue that common study methods for psychiatric drugs may inadvertently minimize withdrawal effects and inflate drug efficacy.
A new research article asserts that the overuse of psychiatric drugs may create neurobiological changes that hamper long-term mental health recovery.
Current long-term users of benzodiazepines and Z-drugs identify barriers and facilitators for discontinuation.
In JAMA Psychiatry, prominent psychiatrist Kenneth Kendler writes that psychiatric diagnoses are “working hypotheses, subject to change.”